Global Hypercalcemia Treatment Market 2017-2021
About Hypercalcemia Treatment
Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by malignancy or hyperparathyroidism. Hypercalcemia is an outcome of overactive parathyroid glands. These four tiny glands are located near thyroid gland and each of them are about the size of a rice grain.
Technavio’s analysts forecast the global hypercalcemia treatment market to grow at a CAGR of 5.44% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hypercalcemia treatment market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hypercalcemia Treatment Market 2017-2021
Technavio recognizes the following companies as the key players in the global hypercalcemia treatment market: AbbVie, Amgen, Merck, Novartis, and OPKO Health.
Other Prominent Vendors in the market are: DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.
Commenting on the report, an analyst from Technavio’s team said: “One trend in market is combination therapy. Although the preference for hypercalcemia drugs in developed countries is increasing, the use of hypercalcemia drugs in combination with other therapies will help maintain the adoption rates. For instance, researchers have evaluated the use of combination drugs, which include pamidronate and calcitonin. This should increase the demand for hypercalcemia drugs in developed countries.”
According to the report, one driver in market is expanding label indications. As the market is dominated by generic products, label extensions will provide more opportunities for revenue generation. This is expected to propel the market growth substantially. Vendors are also increasingly focusing on developing drugs for segments such as parathyroidism and CKD. For instance, in 2016, OPKO Health received approval from the US FDA for Rayaldee (extended-release capsules) for the treatment of SHPT in adults with CKD and serum total 25-hydroxyvitamin D. Also, in November 2016, Amgen received approval from the EC for Parsabiv (etelcalcetide) to treat SHPT in adults with CKD on hemodialysis. In September 2015, Rockwell Medical Launched Calcitriol in the US for the treatment of iron replacement, SHPT, and hemodialysis. The increase in label indications will expand the scope of hypercalcemia, thereby driving the market growth.
Further, the report states that one challenges in market is patent expiries of major drugs. Patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in its sales. The introduction of low-cost drugs is likely to increase the competition in the market. The market has experienced the limited availability of branded products due to the patent expiry of major drugs such as Amgen’s Sensipar, which lost its patent in 2016. Similarly, AbbVie’s ZEMPLAR (paricalcitol) lost its patent in 2015, and Sanofi-Aventis US’s Hectorol (doxercalciferol), which was an intravenous for the treatment of SHPT, had lost its patent in 2014. Thus, the patent expiries of major drugs result in the decline of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit- https://www.technavio.com/report/global-health-and-wellness-global-hypercalcemia-treatment-market-2017-2021
AbbVie, Amgen, Merck, Novartis, OPKO Health, DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.